Clin Exp Immunol. 1986 Sep;65(3):683-90.
Physicians treating patients with antibody deficiency now have a choice between intravenous (IVIG) and intramuscular immunoglobulin therapy. The published comparative trials suggest that (IVIG) is superior, and this is supported by numerous anecdotal observations. Reactions during infusions are no longer a major problem, but there is concern over the transmission of viruses, particularly those causing non-A non-B hepatitis. Having solved the technical difficulties of bulk manufacture of IgG concentrates for intravenous use, our attention should now be directed towards preventing viral contamination by both modifying the manufacturing processes and screening the donors for evidence of disease.
治疗抗体缺乏症患者的医生现在可以在静脉注射免疫球蛋白（IVIG）疗法和肌肉注射免疫球蛋白疗法之间做出选择。已发表的比较试验表明，IVIG更具优势，众多轶事观察结果也支持这一点。输液过程中的反应不再是主要问题，但人们担心病毒传播，尤其是那些导致非甲非乙型肝炎的病毒。在解决了静脉注射用IgG浓缩物大规模生产的技术难题后，我们现在应将注意力转向通过改进生产工艺和筛查献血者的疾病证据来预防病毒污染。
